Antibodies News and Research

RSS

Key lessons from COVID-19 pandemic for scientific and clinical communities

In a paper published in the journal Cell, researchers have investigated and criticized clinical care management and drug administration within the pandemic.

4 Oct 2021

Breakthrough research reveals why some Covid patients may die from the disease

The number of Covid cases in the UK has risen 12% this week, but while some people may be hospitalized, others will suffer little more than a loss of smell. London Medical Laboratory says new research is now revealing everyone’s immune system is as unique as their fingerprint.

4 Oct 2021

Study provides insights on kidney transplant recipients’ immune response to SARS-CoV-2 infection

New research provides insights on the immune responses of kidney transplant recipients following infection with the virus that causes COVID-19. The study, which is published in JASN, may help explain why these individuals face a higher risk of dying from COVID-19 than others in the general population.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical trial, the findings of which have been published in the "The New England Journal of Medicine".

3 Oct 2021

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.

3 Oct 2021

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

A recent study discusses the rate of changes in peripheral blood white cells in individuals who have recovered from SARS-CoV-2 infection.

3 Oct 2021

Cancer patients on chemotherapy have lower immune response to COVID-19 vaccine, study finds

The COVID-19 pandemic has been an especially stressful time for cancer patients undergoing chemotherapy, which attacks not only the cancer, but also the immune cells needed to defend the body from infections.

2 Oct 2021

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

A new preprint describes promising results with a novel vaccine candidate designed to improve the breadth of neutralization.

1 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

A new study reported the persistence of immune responses over twelve months after natural infection.

1 Oct 2021

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Researchers from the University of Oxford have been examining the impact of vaccination on the spread of the Alpha and Delta variants through the population.

1 Oct 2021

Study finds US pediatric COVID-19 cases are higher than expected

Researchers from the CDC have investigated differences in seroprevalence across pediatric age groups to estimate an infection to case ratio.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Additional supportive care services benefit older adults receiving chemotherapy, study finds

A clinical trial led by researchers at City of Hope, a world-renowned cancer research and treatment organization, showed that patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects when a multidisciplinary team of experts analyzed each case and introduced personalized interventions.

30 Sep 2021

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

In a study published today in the American Journal of Transplantation, Johns Hopkins Medicine researchers say that children between the ages of 12 and 18 who have received solid organ transplants appear to mount a more robust immune response than their adult counterparts after a standard two-dose vaccination regimen against SARS-CoV-2, the virus that causes COVID-19.

30 Sep 2021

SARS-CoV-2 nucleocapsid antigen as a possible COVID-19 severity marker

French researchers used a highly sensitive and specific nucleocapsid-Ag assay to explore the relationship between N-Ag in urine during COVID-19 and the severity of the disease in hospitalized patients.

30 Sep 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

Antibodies News and Research

Key lessons from COVID-19 pandemic for scientific and clinical communities

Breakthrough research reveals why some Covid patients may die from the disease

Study provides insights on kidney transplant recipients’ immune response to SARS-CoV-2 infection

Using a new public antibody to understand SARS-CoV-2 neutralization

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

Cancer patients on chemotherapy have lower immune response to COVID-19 vaccine, study finds

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Study finds US pediatric COVID-19 cases are higher than expected

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Additional supportive care services benefit older adults receiving chemotherapy, study finds

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

SARS-CoV-2 nucleocapsid antigen as a possible COVID-19 severity marker

The applications of nanomaterials against viral disease

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News